Month: February 2025

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Written by Customer Service on February 27, 2025. Posted in Earnings Releases And Operating Results.

– Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer (“mCRC”) clinical trial (CRDF-004) – – Priced oversubscribed $40 million underwritten registered direct offering with participation from new and existing healthcare dedicated investors – – Issuance of new patent with claims for the use of onvansertib for treating KRAS-mut mCRC – – Cash and equivalents of $91.7 million as of December 31, 2024, projected runway into Q1 2027 – – Company will hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT – SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

red violet Announces Fourth Quarter and Full Year 2024 Financial Results

Written by Customer Service on February 27, 2025. Posted in Earnings Releases And Operating Results.

Fourth Quarter Revenue Increased 30% to a Record $19.6 Million, Producing $6.7 Million of Cash Flow from Operations Full Year 2024 Revenue Increased 25% to $75.2 Million, Generating GAAP EPS of $0.50 BOCA RATON, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) — Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced financial results for the fourth quarter and full year ended December 31, 2024. “We are proud to announce record-breaking financial results for 2024, including record revenue in the fourth quarter, which marks a significant achievement as we defied the historic seasonality we typically experience during that quarter,” stated Derek Dubner, red violet’s CEO. “The market is recognizing what we have known all along—we have built the leading technology platform with superior solutions...

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

Written by Customer Service on February 27, 2025. Posted in Public Companies.

ALK (ALKB:DC / OMX: ALK B) today announced that the US Food and Drug Administration (FDA) has approved ALK’s ODACTRA® tablet for use in young children with house dust mite (HDM) allergy. ODACTRA® is now indicated to treat HDM-induced allergic rhinitis, with or without conjunctivitis, in children aged five through 11, in addition to patients aged 12 through 65. ODACTRA® is an allergy immunotherapy (AIT) tablet which dissolves under the tongue and helps patients reduce their allergy symptoms and their reliance on symptomatic medication. The FDA approval is an important step in ALK’s efforts to make all its respiratory tablets available for all age groups – children, adolescents, and adults – in all relevant markets. ALK’s Executive Vice President of R&D, Henriette Mersebach (MD), says: “I’m very pleased with the FDA approval...

Extendicare Announces Changes to Board of Directors

Written by Customer Service on February 27, 2025. Posted in Public Companies.

MARKHAM, Ontario, Feb. 27, 2025 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced the appointment of Donald Clow and Heather-Anne Irwin to its board of directors for a term to expire at the next annual meeting of shareholders, whereupon Mr. Clow and Ms. Irwin will stand for election. Concurrent with these appointments, the Company also announced the retirement of Al Mawani from the board of directors after seven years of service. In his time on the board, Mr. Mawani served as a member of various committees, including chair of the Investment Committee. These changes return Extendicare’s board to nine directors. Mr. Clow is a highly regarded executive with deep experience in the real estate sector having held C-suite positions in several organizations. He served as President and CEO of...

Nokia Corporation: Repurchase of own shares on 27.02.2025

Written by Customer Service on February 27, 2025. Posted in Public Companies.

Nokia CorporationStock Exchange Release27 February 2025 at 22:30 EET Nokia Corporation: Repurchase of own shares on 27.02.2025 Espoo, Finland – On 27 February 2025 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 1,400,000 4.72CEUX – –BATE – –AQEU – –TQEX – –Total 1,400,000 4.72* Rounded to two decimals On 22 November 2024, Nokia announced that its Board of Directors is initiating a share buyback program to offset the dilutive effect of new Nokia shares issued to the shareholders of Infinera Corporation and certain Infinera Corporation share-based incentives. The repurchases in compliance with the Market Abuse Regulation (EU) 596/2014...

Microbix Hosts Ontario Premier Doug Ford & Team

Written by Customer Service on February 27, 2025. Posted in Public Companies.

Site Visit & Discussions with Premier Ford & MPP Deepak Anand MISSISSAUGA, Ontario, Feb. 27, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a proudly Ontario Made life sciences innovator, manufacturer, and exporter, was pleased to host Government of Ontario candidates Premier Doug Ford (Etobicoke North riding) and local MPP Deepak Anand (Mississauga-Malton riding). During their site visit on the morning of February 27 — Ontario’s Provincial Election Day — our team had great conversations about how next-generation diagnostic tests can improve health outcomes for patients while also reducing healthcare costs. Microbix’s CEO, Cameron Groome, commented, “We are very pleased for Microbix to be recognized by candidates Premier Ford and MPP Anand as a leading Ontario-based life sciences...

PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA

Written by Customer Service on February 27, 2025. Posted in Public Companies.

TORONTO, Feb. 27, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is proud to announce that its previously announced (See press release of October 8, 2024) contract to the University of Texas Health Science Center at San Antonio (UT Health San Antonio) will move forward, with the trial having been funded by a grant via the Defense Appropriations Act. “This DoD-funded project has the potential to be a game-changer for the treatment of PTSD in active duty military populations,” said Alan Peterson, PhD, professor of psychiatry and behavioral sciences at UT Health San Antonio and director of the STRONG STAR Consortium. The...

2025 Annual General Meeting

Written by Customer Service on February 27, 2025. Posted in Public Companies.

Golar LNG Limited advises that its 2025 Annual General Meeting will be held on Tuesday May 20, 2025. The record date for voting at the Annual General Meeting is set to March 13, 2025. A copy of the notice, agenda and associated material will be distributed to shareholders by normal distribution methods prior to the meeting and will also be made available on the Company’s website at www.golarlng.com Golar LNG LimitedHamilton, BermudaFebruary 27, 2025 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Written by Customer Service on February 27, 2025. Posted in Public Companies.

BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025. Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) and such number of the 2,100,000 shares of Series D Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series D”) held by Seller so that Purchaser...

SJW Group Announces Leadership Transition and Executive Promotions to Drive Continued Growth

Written by Customer Service on February 27, 2025. Posted in Public Companies.

Eric W. Thornburg to retire as Chief Executive Officer and President effective June 30, 2025; will remain on as non-executive Chair of the Board Andrew F. Walters named next Chief Executive Officer Bruce A. Hauk promoted to President Kristen A. Johnson promoted to President of the newly formed Shared Services organizationSAN JOSE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) — SJW Group (NASDAQ: SJW), one of the nation’s largest investor-owned pure-play water and wastewater utilities, today announced a leadership transition that marks the next phase of the company’s strategic direction and planned growth. After eight years of servant leadership and over 40 years of service to the drinking water profession, Eric W. Thornburg will retire as Chief Executive Officer (CEO) and President of SJW Group on June 30, 2025. He will remain on...

Month: February 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals